dc.contributor.author | de la Torre-Tarazona, Humberto Erick | |
dc.contributor.author | Jiménez, R | |
dc.contributor.author | Bueno, P | |
dc.contributor.author | Camarero-Serrano, Sara | |
dc.contributor.author | Román, L | |
dc.contributor.author | Fernández-García, J L | |
dc.contributor.author | Beltran, Manuela | |
dc.contributor.author | Nothias, L F | |
dc.contributor.author | Cachet, X | |
dc.contributor.author | Paolini, J | |
dc.contributor.author | Litaudon, M | |
dc.contributor.author | Alcamí, José | |
dc.contributor.author | Bedoya, Luis M | |
dc.date.accessioned | 2020-11-13T13:23:32Z | |
dc.date.available | 2020-11-13T13:23:32Z | |
dc.date.issued | 2020-07 | |
dc.identifier.citation | Biochem Pharmacol. 2020 Jul;177:113937. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/11339 | |
dc.description.abstract | Latent HIV reservoirs are the main obstacle to eradicate HIV infection. One strategy proposes to eliminate these viral reservoirs by pharmacologically reactivating the latently infected T cells. We show here that a 4-deoxyphorbol ester derivative isolated from Euphorbia amygdaloides ssp. semiperfoliata, 4β-dPE A, reactivates HIV-1 from latency and could potentially contribute to decrease the viral reservoir. 4β-dPE A shows two effects in the HIV replication cycle, infection inhibition and HIV transactivation, similarly to other phorboids PKC agonists such PMA and prostratin and to other diterpene esters such SJ23B. Our data suggest 4β-dPE A is non-tumorigenic, unlike the related compound PMA. As the compounds are highly similar, the lack of tumorigenicity by 4β-dPE A could be due to the lack of a long side lipophilic chain that is present in PMA. 4β-dPE activates HIV transcription at nanomolar concentrations, lower than the concentration needed by other latency reversing agents (LRAs) such as prostratin and similar to bryostatin. PKCθ/MEK activation is required for the transcriptional activity, and thus, anti-latency activity of 4β-dPE A. However, CD4, CXCR4 and CCR5 receptors down-regulation effect seems to be independent of PCK/MEK, suggesting the existence of at least two different targets for 4β-dPE A. Furthermore, NF-κb transcription factor is involved in 4β-dPE HIV reactivation, as previously shown for other PKCs agonists. We also studied the effects of 4β-dPE A in combination with other LRAs. When 4β-dPE A was combined with another PKC agonists such as prostratin an antagonic effect was achieved, while, when combined with an HDAC inhibitor such as vorinostat, a strong synergistic effect was obtained. Interestingly, the latency reversing effect of the combination was synergistically diminishing the EC50 value but also increasing the efficacy showed by the drugs alone. In addition, combinations of 4β-dPE A with antiretroviral drugs as CCR5 antagonist, NRTIs, NNRTIs and PIs, showed a consistent synergistic effect, suggesting that the combination would not interefer with antiretroviral therapy (ART). Finally, 4β-dPE A induced latent HIV reactivation in CD4 + T cells of infected patients under ART at similar levels than the tumorigenic phorbol derivative PMA, showing a clear reactivation effect. In summary, we describe here the mechanism of action of a new potent deoxyphorbol derivative as a latency reversing agent candidate to decrease the size of HIV reservoirs. | es_ES |
dc.description.sponsorship | This work was supported by Ministry of Education of the Peruvian government (PRONABEC), the Universidad Complutense de Madrid (UCM-Santander PR87/19), the Instituto de Salud Carlos III (ISCIII-FIS PI16CIII/00034) and the Spanish AIDS Research Network RD12/0017/0015 that is included in the Spanish I D I Plan and is co-financed by ISCIII-Subdirección General de Evaluación and European Funding for Regional Development (FEDER). This work has also benefited from an “Investissement d’Avenir” grant managed by Agence Nationale de la Recherche (CEBA, ANR- 10-LABX-25-01). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | SMUR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | HIV-1 | es_ES |
dc.subject | Latency reversing agents | es_ES |
dc.subject | Phorbol esters | es_ES |
dc.subject | Protein kinase C | es_ES |
dc.subject | Viral reactivation | es_ES |
dc.title | 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 32224142 | es_ES |
dc.format.volume | 177 | es_ES |
dc.format.page | 113937 | es_ES |
dc.identifier.doi | 10.1016/j.bcp.2020.113937 | es_ES |
dc.contributor.funder | Complutense University of Madrid (España) | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Red de Investigación Cooperativa en Investigación en Sida (España) | |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
dc.contributor.funder | Agence Nationale de la Recherche (Francia) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1873-2968 | |
dc.relation.publisherversion | https://doi.org/10.1016/j.bcp.2020.113937 | es_ES |
dc.identifier.journal | Biochemical pharmacology | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/UCM-Santander PR87/19 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI16CIII/00034 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RD12/0017/0015 | es_ES |
dc.rights.accessRights | open access | es_ES |